In summary, post–BT infection in vaccinated patients with HM, there was a significant CD4+ T-cell and Tfh rise but not CD8+ T-cell rise, with no impact on prior receipt of B-cell–depleting therapy in the last 12 months. Here, CD8A is linked to infection.